Cardiovascular Effects of Metformin

Cardiovascular Effects of Metformin

Type 2 diabetes mellitus is one of the most important independent risk factors for the development, progression and mortality from cardiovascular diseases (CVD). The world communities are faced with the question of developing the optimal management tactics for such comorbidity patients. Thus, the pr...

Full description

Bibliographic Details
Main Authors:	B. T. Kurmanbekova, A. M. Noruizbaeva
Format:	Article
Language:	English
Published:	Столичная издательская компания 2022-03-01
Series:	Рациональная фармакотерапия в кардиологии
Subjects:	metformin cardiovascular disease cardioprotective properties
Online Access:	https://www.rpcardio.online/jour/article/view/2664

Similar Items

Effects of Metformin on Ischemia/Reperfusion Injury: New Evidence and Mechanisms
by: Estefanie Osorio-Llanes, et al.
Published: (2023-08-01)

Where Does Metformin Stand in Modern Day Management of Type 2 Diabetes?
by: Ehtasham Ahmad, et al.
Published: (2020-11-01)

Metformin: Activation of 5′ AMP-activated protein kinase and its emerging potential beyond anti-hyperglycemic action
by: Sanjay Goel, et al.
Published: (2022-10-01)

Metformin and high-sensitivity cardiac troponin I and T trajectories in type 2 diabetes patients: a post-hoc analysis of a randomized controlled trial
by: Johanna M. G. Stultiens, et al.
Published: (2022-04-01)

The Current and Potential Therapeutic Use of Metformin—The Good Old Drug
by: Józef Drzewoski, et al.
Published: (2021-02-01)

Cardiovascular effects of metformin: focus on adipose tissue metabolism
by: Olga V. Gruzdeva, et al.
Published: (2022-09-01)

TRH and TRH-like peptide levels covary with caloric restriction and oral metformin in rat heart and testis
by: Albert Eugene Pekary, et al.
Published: (2022-06-01)

Reliability of Metformin’s protective effects against doxorubicin-induced cardiotoxicity: a meta-analysis of animal studies
by: Ming-Li Sun, et al.
Published: (2024-08-01)

Gastrointestinal Mechanisms Underlying the Cardiovascular Effect of Metformin
by: Malcolm J. Borg, et al.
Published: (2020-11-01)

Metformin: A Narrative Review of Its Potential Benefits for Cardiovascular Disease, Cancer and Dementia
by: Wiebe M. C. Top, et al.
Published: (2022-03-01)

Therapeutic Effects and Safe Uses of Plant-Derived Polyphenolic Compounds in Cardiovascular Diseases: A Review
by: Alotaibi BS, et al.
Published: (2021-11-01)

Metformin Protects Cardiovascular Health in People With Diabetes
by: Chong Chen, et al.
Published: (2022-07-01)

Risk of antidepressant initiation among users of cardiovascular agents and metformin.
by: Ivana Bojanić, et al.
Published: (2023-04-01)

Association of metformin and statin medications with surrogate measures of cardiovascular disease in youth with type 1 diabetes: the SEARCH for diabetes in youth study
by: Evgenia Gourgari, et al.
Published: (2019-09-01)

Cardiovascular outcomes of metformin use in patients with type 2 diabetes and chronic obstructive pulmonary disease
by: Fu-Shun Yen, et al.
Published: (2022-08-01)

Metformin reduces the risk of developing influenza A virus related cardiovascular disease
by: Han Sol Lee, et al.
Published: (2023-10-01)

Effect of Dietary Phenolic Compounds on Incidence of Cardiovascular Disease in the SUN Project; 10 Years of Follow-Up
by: Zenaida Vázquez-Ruiz, et al.
Published: (2022-04-01)

Editorial: Nutraceuticals in cardiovascular diseases and their associated risk conditions
by: Lamiaa Ahmed, et al.
Published: (2024-09-01)

Evaluating the cardioprotective effect of metformin on myocardial ischemia–reperfusion injury using dynamic 18F-FDG micro-PET/CT imaging
by: Hang Su, et al.
Published: (2022-07-01)

Visfatin/PBEF/Nampt: a new cardiovascular target?
by: Concepción ePeiró, et al.
Published: (2010-11-01)

Metformin as a medicine decreasing cardiovascular risk in patients suffering from type 2 diabetes mellitus
by: Małgorzata Wieteska, et al.
Published: (2020-08-01)

Potential therapeutic mechanisms of Draconis Resina in cardiovascular diseases-a narrative review
by: Jing Wang, et al.
Published: (2025-03-01)

Berberis vulgaris for cardiovascular disorders: a scoping literature review
by: Abdelrahman Abushouk, et al.
Published: (2017-05-01)

Impact of canagliflozin combined with metformin therapy on reducing cardiovascular risk in type 2 diabetes patients
by: Xiaoyu Chen, et al.
Published: (2024-08-01)

Beneficial Effects of Polyphenol-Rich Food Oils in Cardiovascular Health and Disease
by: Lucia Kindernay, et al.
Published: (2023-07-01)

Editorial: Cardiovascular adaptation to extreme environment
by: Alessandro Pingitore, et al.
Published: (2022-09-01)

Primary prevention of cardiovascular diseases in diabetes mellitus: 2020 strategy
by: V. I. Novikov, et al.
Published: (2020-05-01)

Real‐world risk of cardiovascular diseases in patients with type 2 diabetes associated with sodium–glucose cotransporter 2 inhibitors in comparison with metformin: A propensity score‐matched model analysis in Japan
by: Takeshi Horii, et al.
Published: (2023-11-01)

Effects of scutellarin on the mechanism of cardiovascular diseases: a review
by: Xinyu Zhang, et al.
Published: (2024-01-01)

Metformin in skin diseases
by: Damian Kadylak, et al.
Published: (2021-05-01)

Time trends of cardiovascular risk management in type 1 diabetes - nationwide analyses of real-life data
by: Hanan Amadid, et al.
Published: (2022-11-01)

The Role of Angiotensin‐Converting Enzyme Inhibitors and β‐Blockers in Primary Prevention of Cardiac Dysfunction in Breast Cancer Patients
by: Sherry‐Ann Brown, et al.
Published: (2020-01-01)

Back to basics with active lifestyles: exercise is more effective than metformin to reduce cardiovascular risk in older adults with type 2 diabetes
by: Liliana C. Baptista, et al.
Published: (2018-09-01)

Atherosclerosis preventive effects of marrubiin against (TNF-α)-induced oxidative stress and apoptosis
by: Ailar Nakhlband, et al.
Published: (2023-09-01)

Comparison of the clinical effect of empagliflozin on glycemic and non-glycemic parameters in Japanese patients with type 2 diabetes and cardiovascular disease treated with or without baseline metformin
by: Atsushi Tanaka, et al.
Published: (2021-07-01)

Metformin therapy in patients with diabetes mellitus is associated with a reduced risk of vasculopathy and cardiovascular mortality after heart transplantation
by: Eilon Ram, et al.
Published: (2019-09-01)

Effect of sildenafil citrate on the cardiovascular system
by: K. Shinlapawittayatorn, et al.
Published: (2005-09-01)

Pleiotropic Effects of Metformin in Osteoarthritis
by: Sevdalina Nikolova Lambova
Published: (2023-02-01)

Caveolin as a Potential Drug Target for Cardiovascular Protection
by: Stephanie L Sellers, et al.
Published: (2012-07-01)

Cardioprotective measures in patients with cardiovascular risk factors and polymorbidity
by: article Editorial
Published: (2022-10-01)